Taiwan's Bio-Age Secures China Approval for Kidney Disease Drug Nephoxil®

Taiwanese biotech firm Bio-Age (寶齡富錦) has achieved a significant breakthrough with its kidney disease drug, Nephoxil® 500mg Capsule, securing approval from China's National Medical Products Administration (NMPA). This landmark decision not only validates the company's innovative research and development but also opens the door to the world's largest market for dialysis patients.

Nephoxil®, developed independently by Bio-Age, is a pioneering medication that utilizes a pharmaceutical-grade iron citrate coordination complex. Its unique dual action effectively lowers blood phosphorus levels while simultaneously addressing iron-deficiency anemia, a common complication for kidney patients. The drug has already garnered approvals in major markets including the United States, Japan, Taiwan, South Korea, Thailand, and Europe, underscoring its global significance and efficacy.

The approval in China is particularly momentous given the country's vast patient population. With approximately 1.18 million dialysis patients as of December 2024, China presents an unparalleled commercial opportunity for Bio-Age. This expansion is a crucial step in the company's global strategy, solidifying Nephoxil®'s position as a leading treatment option for kidney disease patients worldwide.

This achievement is a source of pride for Taiwan's burgeoning biotechnology sector, showcasing the island's capability in developing innovative pharmaceuticals for global markets. Bio-Age's success with Nephoxil® serves as an inspiration and a testament to the potential of Taiwanese companies to compete on the international stage, bringing much-needed medical advancements to patients across the globe.